Browsing Tag
United States
1080 posts
Iraganaboyina Chandu death in US puts spotlight on Indian student distress abroad
Indian students chase United States careers with family debt behind them. Iraganaboyina Chandu’s death shows how fragile that pathway can become.
The Turnberry Agreement: Inside the asymmetric United States and European Union trade framework now under strain
Brussels accepted a 15 per cent tariff ceiling for stability. Trump just breached it. The Turnberry Agreement was the floor, not the deal.
Why Nebraska’s Medicaid work requirements rollout is now a national test case
Nebraska moved first on Medicaid work rules. The real test is whether eligibility systems can protect coverage while enforcing compliance.
How China’s lithium processing dominance is forcing the West to rethink industrial policy
The West has lithium mines and battery ambitions. China still controls the refining layer that turns critical minerals into real industrial power.
European oil majors abandon unified energy transition framework as TotalEnergies, Shell, BP, Eni and Equinor pursue different paths
TotalEnergies hikes dividends. Shell buys back stock. BP retreats from transition. Eni engineers sell-downs. Equinor exits wind. Same oil price, five answers.
Hydreight Technologies turns profitable as VSDHOne reshapes the NURS stock growth story
Hydreight has growth and profit, but platform scale brings scrutiny. Read why VSDHOne is now central to the NURS stock story.
Oil market whiplash: Brent crude retreats after U.S.-Iran escalation fears
Oil fell after a $126 spike, but U.S.-Iran war risk still hangs over supply, inflation, and the Strait of Hormuz.
Uber stock faces a new super-app test as Expedia powers hotel bookings inside Uber
Uber wants more than rides. Expedia gives it hotels, but the real test is whether travelers trust one app to run the whole trip.
AstraZeneca Q1 2026 results: Can oncology and rare disease growth keep AZN’s 2030 ambition on track?
AstraZeneca’s growth engine is firing, but pricing pressure and launch risk still loom. Can oncology and rare disease carry AZN to 2030?
GSK’s bepirovirsen wins FDA priority review as chronic hepatitis B strategy enters decisive phase
GSK has FDA momentum in hepatitis B. The harder question is whether bepirovirsen can turn functional cure into a real market shift.